RxDoctor Payments Data

Akshay Shetty

Gastroenterology · Los Angeles, CANPI 1265790687

Payments from drug & device makers

$68,585in general payments, 2019–2025

Across 137 payments — averaging $500.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch Health US, LLC$51K
  • Madrigal Pharmaceuticals$8K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • Ipsen Biopharmaceuticals, Inc$3K
  • Gilead$2K
  • AbbVie$249
  • plus $721 from 8 others

What the payments were for

  • Consulting fees$9,70055%
  • Speaking & faculty fees$2,76016%
  • Travel & lodging$9465%
  • Food & beverage$4,08823%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,585 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$81,360
Medicare patients
344
Services billed
722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezdiffraResmetirom27$103,325
XifaxanRifaximin31$103,261
VemlidyTenofovir Alafenamide52$71,811
EliquisApixaban18$12,018
OzempicSemaglutide11$11,297
Lactulose87$4,747
Ursodiol35$2,086
Mycophenolate Mofetil16$710
Pantoprazole Sodium47$673
Spironolactone73$671
Furosemide84$366
Rosuvastatin Calcium11$275
Entecavir12$224
FenofibrateFenofibrate Nanocrystallized11$210
Prednisone16$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Madrigal PharmaceuticalsRezdiffra$7,858$103,32527 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$3,688$103,26131 claims
GileadVemlidy$2,165$71,81152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →